(Q34306890)

1 August 2017

1 reference

title

Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer (English)

1 reference

1 August 2017

1 reference

Ruth Whittington

1

1 reference

PubMed ID

7693434

1 August 2017

Diana Faulds

series ordinal

2

1 reference

1 August 2017

1 September 1993

1 reference

1 August 2017

1 reference

1 August 2017

46

1 reference

1 August 2017

3

1 reference

1 August 2017

446-514

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199346030-00009

1 August 2017

0 references

cites work

Biodistribution and pharmacokinetics of recombinant, human 125I-interleukin-2 in mice

1 reference

12 December 2020

Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma

1 reference

12 December 2020

Differential effects of interleukin-2 and interleukin-4 on protein tyrosine phosphorylation in factor-dependent murine T cells

1 reference

12 December 2020

Continuous infusion of interleukin-2 and cyclophosphamide as treatment of advanced cancers: a National Biotherapy Study Group Trial

1 reference

12 December 2020

Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience.

1 reference

12 December 2020

Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis

1 reference

12 December 2020

Thyroid disorders in 2 cases of acute myeloid leukaemia following treatment with recombinant interleukin-2 infusion

1 reference

12 December 2020

Phase I Trial of Interleukin-2 plus Gamma-Interferon

1 reference

12 December 2020

Interleukin-2 enhances biopterins and catecholamines production during adoptive immunotherapy for various cancers.

1 reference

12 December 2020

The interleukin 2 receptor. Functional consequences of its bimolecular structure

1 reference

12 December 2020

A multicenter trial of interleukin-2 and low-dose cyclophosphamide in highly chemotherapy-resistant malignancies

1 reference

12 December 2020

Increased numbers of circulating haematopoietic progenitor cells after treatment with high-dose interleukin-2 in cancer patients

1 reference

12 December 2020

Intrapleural immunotherapy with escalating doses of interleukin-2 in metastatic pleural effusions

1 reference

12 December 2020

Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.

1 reference

12 December 2020

Interferon-alpha can synergize with interleukin 2 for human in vitro antibody response

1 reference

12 December 2020

Prognostic factors in metastatic renal carcinoma

1 reference

12 December 2020

Autoimmune Thyroiditis following Interleukin-2 and Lak Cell Therapy for Metastatic Renal Cell Carcinoma: Correlation with Tumor Regression

1 reference

12 December 2020

A phase-II trial of recombinant interleukin-2 and 5-FU chemotherapy in patients with metastatic colorectal carcinoma

1 reference

12 December 2020

Phase II trial of outpatient interleukin-2 in malignant lymphoma, chronic lymphocytic leukemia, and selected solid tumors

1 reference

12 December 2020

Human recombinant interleukin-2 as an experimental therapeutic

1 reference

12 December 2020

Glutathione regulates interleukin-2 activity on cytotoxic T-cells

1 reference

12 December 2020

Efficacy of low doses of the polyethylene glycol derivative of interleukin-2 in modulating the immune response of patients with human immunodeficiency virus type 1 infection

1 reference

12 December 2020

Production of tumor necrosis factor alpha and interferon gamma in interleukin-2-treated melanoma patients: correlation with clinical toxicity

1 reference

12 December 2020

Thrombocytopenia in acute leukaemia patients treated with IL2: cytolytic effect of LAK cells on megakaryocytic progenitors

1 reference

12 December 2020

Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma

1 reference

12 December 2020

Thyroid dysfunction associated with immunotherapy for patients with cancer

1 reference

12 December 2020

Thyroiditis after treatment with interleukin-2 and interferon alpha-2a

1 reference

12 December 2020

Pulmonary edema as a complication of interleukin-2 therapy

1 reference

12 December 2020

Internalization of interleukin 2 is mediated by the beta chain of the high-affinity interleukin 2 receptor

1 reference

12 December 2020

Intracavitary administration of interleukin-2 as palliative therapy for neoplastic effusions

1 reference

12 December 2020

Association of interleukin-2 therapy with staphylococcal bacteremia

1 reference

12 December 2020

Lymphocyte activation and serine-esterase induction following recombinant interleukin-2 infusion for lymphomas and acute leukaemias

1 reference

12 December 2020

Infectious complications associated with interleukin-2 administration: a retrospective review of 935 treatment courses

1 reference

12 December 2020

Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen

1 reference

12 December 2020

Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2.

1 reference

12 December 2020

Circulating intercellular adhesion molecule-1 in melanoma patients: induction by interleukin-2 therapy.

1 reference

12 December 2020

A comprehensive macrophage-T-lymphocyte theory of schizophrenia

1 reference

12 December 2020

Regulation of IL-2 receptor subunit genes in human monocytes. Differential effects of IL-2 and IFN-gamma

1 reference

12 December 2020

The interaction of interleukin 2 with its receptor in the generation of suppressor T cells in antigen-specific and antigen-nonspecific systems in vitro

1 reference

12 December 2020

Interferons and interleukins in metastatic renal cell carcinoma

1 reference

12 December 2020

Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.

1 reference

12 December 2020

The lymphatic route. VII. Distribution of recombinant human interleukin-2 in rabbit plasma and lymph

1 reference

12 December 2020

Interleukin-2-induced chemotaxis of human T-lymphocytes

1 reference

12 December 2020

Peripheral blood lymphocyte number and phenotype prior to therapy correlate with response in subcutaneously applied rIL-2 therapy of renal cell carcinoma

1 reference

12 December 2020

Augmentation of recombinant interleukin-2-dependent murine macrophage-mediated tumour cytotoxicity by recombinant tumour necrosis factor-alpha

1 reference

12 December 2020

Membrane-associated interleukin 2 epitopes on the surface of human T lymphocytes

1 reference

12 December 2020

Pilot Study of Interleukin-2 and Lymphokine-Activated Killer Cells Combined With Immunomodulatory Doses of Chemotherapy and Sequenced With Interferon Alfa-2a in Patients With Metastatic Melanoma and Renal Cell Carcinoma

1 reference

12 December 2020

A phase-II study of adoptive immunotherapy with continuous infusion of interleukin-2 in children with advanced neuroblastoma. A report on 11 cases

1 reference

12 December 2020

Lymphokine-activated killer cell and interleukin-2 inhibitors: their role in adoptive immunotherapy

1 reference

12 December 2020

The efficacy of recombinant interleukin 2 in local treatment of superficial bladder tumors

1 reference

12 December 2020

The effect of intravenous interleukin-2 on brain water content

1 reference

12 December 2020

The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma

1 reference

12 December 2020

The promotive effect of interleukin 4 with interleukin 2 in the proliferation of tumor-infiltrating lymphocytes from patients with malignant tumor

1 reference

12 December 2020

The effects of recombinant interleukin 2 on HBe antigen positive chronic hepatitis B

1 reference

12 December 2020

Prostaglandin E2-mediated suppression of murine lymphokine-activated killer cell activity generated from tumor-bearing hosts by interferon-gamma.

1 reference

12 December 2020

Functional and molecular characterization of a monoclonal antibody against human interleukin 2

1 reference

12 December 2020

[Infectious complications during treatments with interleukin-2]

1 reference

12 December 2020

Effect of prolonged subcutaneous administration of interleukin-2 on the circadian rhythms of cortisol and beta-endorphin in advanced small cell lung cancer patients

1 reference

12 December 2020

Treatment of recurrent in transit metastases from cutaneous melanoma by isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine activated killer cells. A pilot study

1 reference

12 December 2020

Recombinant interleukin-2: a biological response modifier

1 reference

12 December 2020

A phase I study of recombinant interleukin-2 intraperitoneal infusion in patients with neoplastic ascites: toxic effects and immunologic results

1 reference

12 December 2020

Cytotoxic in vitro function in patients with metastatic renal cell carcinoma before and after alpha-2b-interferon therapy. Effects of activation with recombinant interleukin-2

1 reference

12 December 2020

Malignant melanoma--profile of an epidemic

1 reference

12 December 2020

IL-4 regulates IL-2 induction of lymphokine-activated killer activity from human lymphocytes

1 reference

12 December 2020

Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial

1 reference

12 December 2020

Studies on the contact system of coagulation during therapy with high doses of recombinant IL-2: implications for septic shock

1 reference

12 December 2020

Quantification of recombinant interleukin-2 in human serum by a specific immunobioassay

1 reference

12 December 2020

Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation

1 reference

12 December 2020

Early sCD8 plasma levels during subcutaneous rIl-2 therapy in patients with renal cell carcinoma correlate with response

1 reference

12 December 2020

In vivo biological results of the association between interleukin-2 and interleukin-3 in the immunotherapy of cancer

1 reference

12 December 2020

Interleukin-2: use in solid tumors

1 reference

12 December 2020

Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor response

1 reference

12 December 2020

Lymphokine-activated killer cells. Analysis of progenitors and effectors

1 reference

12 December 2020

Cytokine responses to intraventricular injection of interleukin 2 into patients with leptomeningeal carcinomatosis: rapid induction of tumor necrosis factor alpha, interleukin 1 beta, interleukin 6, gamma-interferon, and soluble interleukin 2 recept

1 reference

12 December 2020

The systemic complement activation caused by interleukin-2/lymphokine-activated killer-cell therapy of cancer causes minimal systemic neutrophil activation

1 reference

12 December 2020

In vivo activity of solid phase interleukin 2

1 reference

12 December 2020

Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies

1 reference

12 December 2020

Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patients.

1 reference

12 December 2020

Reduction of Testosterone Synthesis after High Dose Interleukin-2 Therapy of Metastatic Cancer*

1 reference

12 December 2020

Augmentation of antitumor effect on syngeneic murine solid tumors by an interleukin 2 slow delivery system, the IL-2 mini-pellet

1 reference

12 December 2020

Antitumor effects of a new interleukin-2 slow delivery system on methylcholanthrene-induced fibrosarcoma in mice

1 reference

12 December 2020

Phase II study of intravenous bolus recombinant interleukin-2 in advanced malignant melanoma: Southwest Oncology Group study

1 reference

12 December 2020

The lymphatic route. VIII. Distribution and plasma clearance of recombinant human interleukin-2 after SC administration with albumin in patients

1 reference

12 December 2020

In vivo production of interleukin-5, granulocyte-macrophage colony-stimulating factor, macrophages colony-stimulating factor, and interleukin-6 during intravenous administration of high-dose interleukin-2 in cancer patients

1 reference

12 December 2020

Pharmacokinetics of recombinant interleukin 2 in humans

1 reference

12 December 2020

Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes

1 reference

12 December 2020

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

12 December 2020

Effects of recombinant human interleukin-2 and excipient infusion on plasma levels of prostaglandins and thromboxane B2 in sheep

1 reference

12 December 2020

Phase I study of intra-arterial interleukin-2 in squamous cell carcinoma of the head and neck

1 reference

12 December 2020

Changes in the host natural killer cell population in mice during tumor development. 2. The mechanism of suppression of NK activity

1 reference

12 December 2020

Involvement of cyclic adenosine monophosphate in the interleukin 4 inhibitory effect on interleukin 2-induced lymphokine-activated killer generation

1 reference

12 December 2020

Modulation of Macrophage Response to Interleukin-2 Immunotherapy by Interleukin-3 in Cancer Patients

1 reference

12 December 2020

Interleukin 2 therapy in severe atopic dermatitis

1 reference

12 December 2020

Appearance of cytokine-associated central nervous system myelin damage coincides temporally with serum tumor necrosis factor induction after recombinant interleukin-2 infusion in rats

1 reference

12 December 2020

Intrapleural application of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer. A multi-institutional cooperative study

1 reference

12 December 2020

Recombinant IL-2 given intra-splenically and intravenously in advanced malignant melanoma: a phase I/II study

1 reference

12 December 2020

Lack of effect of tumour infiltrating lymphocytes in patients with metastatic melanoma who failed to respond to interleukin 2

1 reference

12 December 2020

Alloimmune cells consume interleukin-2 and competitively inhibit the anti-tumour effects of interleukin-2

1 reference

12 December 2020

In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2

1 reference

12 December 2020

Interleukin-2 therapy for refractory and relapsing lymphomas

1 reference

12 December 2020

Correlation of eosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin C

1 reference

12 December 2020

Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells

1 reference

12 December 2020

Recombinant interleukin 2 for acute myeloid leukaemia in first complete remission: a pilot study

1 reference

12 December 2020

Pharmacokinetics of recombinant interleukin-2 in children with malignancies: a Pediatric Oncology Group study

1 reference

12 December 2020

Immunization with interleukin-2 transfected melanoma cells. A phase I-II study in patients with metastatic melanoma

1 reference

12 December 2020

Atrioventricular block following therapy with recombinant interleukin 2

1 reference

12 December 2020

Differences between in vivo and in vitro activation of cancer patient lymphocytes by recombinant interleukin 2: possible role for lymphokine-activated killer cell infusion in the in vivo-induced activation

1 reference

12 December 2020

Neuroimmunotherapy with Subcutaneous Low-Dose Interleukin-2 and the Pineal Hormone Melatonin as a Second-Line Treatment in Metastatic Colorectal Carcinoma

1 reference

12 December 2020

Interleukin-2 therapy for advanced renal cell carcinoma: radiographic evaluation of response and complications

1 reference

12 December 2020

Rapid cytokine release in cancer patients treated with interleukin-2

1 reference

12 December 2020

Response of soluble IL-2 receptor levels to repeated cycles of IL-2 immunotherapy/chemotherapy

1 reference

12 December 2020

Thyroid functions in patients treated with interleukin-2 and lymphokine-activated killer cells

1 reference

12 December 2020

Local continuous high dose interleukin 2: a new therapeutic model for the treatment of advanced bladder carcinoma.

1 reference

12 December 2020

Lack of interleukin-2 (IL-2) dependent growth of TAC positive T-ALL/NHL cells is due to the expression of only low affinity receptors for IL-2

1 reference

12 December 2020

Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines

1 reference

12 December 2020

Use of recombinant IL-2 (RU49637) after autologous bone marrow transplantation (BMT) in patients with hematological neoplasias: a phase 1 study

1 reference

12 December 2020

Lithium clearance measurements during recombinant interleukin 2 treatment: tubular dysfunction in man

1 reference

12 December 2020

Interleukin 2 therapy in cancer: identification of responders

1 reference

12 December 2020

Neuro-ophthalmic Complications of Interleukin 2 Therapy

1 reference

12 December 2020

Evaluation of the safety of recombinant interleukin-2 (rIL-2) and rIL-2 plus 5-fluorouracil (5-FU) in the adjuvant treatment of gastric cancer patients

1 reference

12 December 2020

Survival after phase II treatment of advanced renal cell carcinoma with taxol or high-dose interleukin-2

1 reference

12 December 2020

A phase I study of subcutaneous recombinant interleukin-2 and interferon alfa-2a

1 reference

12 December 2020

A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects

1 reference

12 December 2020

Pharmacokinetics of repeated i.v. bolus administration of high doses of r-met-Hu interleukin-2 in advanced cancer patients

1 reference

12 December 2020

Interleukin-2 dose, blood monocyte and CD25+ lymphocyte counts as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma

1 reference

12 December 2020

Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma.

1 reference

12 December 2020

Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.

1 reference

12 December 2020

Phase I Study of Low-Dose Cyclophosphamide and Recombinant Interleukin-2 for the Treatment of Advanced Cancer

1 reference

12 December 2020

Bacterial infections in lymphoma patients treated with recombinant interleukin-2

1 reference

12 December 2020

Interleukin-2 toxicity

1 reference

12 December 2020

Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial

1 reference

12 December 2020

A pilot study of immunization with HLA-A2 matched allogeneic melanoma cells that secrete interleukin-2 in patients with metastatic melanoma

1 reference

12 December 2020

Inhibitory effect of interleukin-3 on interleukin-2-induced cortisol release in the immunotherapy of cancer

1 reference

12 December 2020

Cardiotoxicity of human recombinant interleukin-2 in rats. A morphological study

1 reference

12 December 2020

Autologous Tumor-Specific Cytotoxicity of Tumor-Infiltrating Lymphocytes Derived from Human Renal Cell Carcinoma

1 reference

12 December 2020

Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells

1 reference

12 December 2020

Tumor-associated eosinophilia in interleukin-2-treated patients: evidence of toxic eosinophil degranulation on bladder cancer cells

1 reference

12 December 2020

Decrease in cholesterol levels during the immunotherapy of cancer with interleukin-2.

1 reference

12 December 2020

Acute lymphoblastic leukemia of NK-cell lineage: responses to IL-2

1 reference

12 December 2020

Adrenal insufficiency and interleukin-2 therapy

1 reference

12 December 2020

Sequential dacarbazine/cisplatin and interleukin-2 in metastatic melanoma: immunological effects of therapy

1 reference

12 December 2020

[Cancer of the kidney: changes in blood lymphocyte subsets induced by treatment with interferon alpha-2b and interleukin-2r]

1 reference

12 December 2020

Hypovitaminosis C in patients treated with high-dose interleukin 2 and lymphokine-activated killer cells

1 reference

12 December 2020

Intraperitoneal infusion of recombinant interleukin-2 in malignant ascites in patients with gastrointestinal and ovarian cancer

1 reference

12 December 2020

Immunotherapy using Freund's adjuvant and recombinant interleukin-2 combined with transarterial chemoembolization for hepatocellular carcinoma.

1 reference

12 December 2020

Sequential chemoimmunotherapy in the treatment of metastatic melanoma

1 reference

12 December 2020

Diminished expression of interleukin-2 receptors in vivo after prior chemotherapy in advanced cancer patients receiving recombinant interleukin-2.

1 reference

12 December 2020

IL-4 and IL-2 promote human T-cell proliferation through symmetrical but independent pathways

1 reference

12 December 2020

Administration of interleukin-2 (IL-2) results in increased plasma concentrations of IL-5 and eosinophilia in patients with cancer.

1 reference

12 December 2020

A phase I study of interleukin-2 in children with cancer

1 reference

12 December 2020

Perioperative immunotherapy with recombinant interleukin 2 in patients undergoing surgery for colorectal cancer

1 reference

12 December 2020

Exacerbation of epidemic Kaposi's sarcoma with a combination of interleukin-2 and beta-interferon: results of a phase 2 study

1 reference

12 December 2020

Interleukin 2 counteracts the inhibition of cytotoxic T lymphocytes by cholera toxin in vitro and in vivo

1 reference

12 December 2020

Immunological and clinical effects of intramuscular rIFN alpha-2a and low dose subcutaneous rIL-2 in patients with advanced malignant melanoma

1 reference

12 December 2020

Lowest dose interleukin-2 immunotherapy.

1 reference

12 December 2020

Interleukin-2 and lymphokine-activated killer cell therapy for gastrointestinal cancer

1 reference

12 December 2020

Phase I/II study of low-dose intravenous OKT3 and subcutaneous interleukin-2 in metastatic cancer

1 reference

12 December 2020

Effect of human recombinant interferon on cytotoxic activity of natural killer (NK) cells and monocytes

1 reference

12 December 2020

Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer

1 reference

12 December 2020

A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma

1 reference

12 December 2020

A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma

1 reference

12 December 2020

Interleukin 4 counteracts the interleukin 2-induced proliferation of monoclonal B cells

1 reference

12 December 2020

A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions

1 reference

12 December 2020

Rapamycin-induced inhibition of p34cdc2 kinase activation is associated with G1/S-phase growth arrest in T lymphocytes

1 reference

12 December 2020

Endolymphatic delivery of IL2 in patients with melanoma and lymphoma

1 reference

12 December 2020

Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors

1 reference

12 December 2020

Local activation of immune response in bladder cancer patients treated with intraarterial infusion of recombinant interleukin-2

1 reference

12 December 2020

Acute renal dysfunction during interleukin-2 treatment: suggestion of an intrinsic renal lesion

1 reference

12 December 2020

Myocarditis or acute myocardial infarction associated with interleukin-2 therapy for cancer

1 reference

12 December 2020

Acute myeloid leukaemia relapsing following interleukin-2 treatment expresses the alpha chain of the interleukin-2 receptor

1 reference

12 December 2020

Immunotherapy with interleukin-2 by constant infusion with and without adoptive cell transfer and with weekly doxorubicin

1 reference

12 December 2020

Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha

1 reference

12 December 2020

Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects

1 reference

12 December 2020

Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: a single-center phase II study

1 reference

12 December 2020

Immunotherapy with interleukin 2 after ABMT in AML

1 reference

12 December 2020

Therapy of advanced acute myeloblastic leukemia with cytarabine and interleukin 2

1 reference

12 December 2020

Interleukin-2-induced lung injury is mediated by oxygen free radicals

1 reference

12 December 2020

A phase I/II trial of recombinant interleukin-2 in AIDS/ARC: alterations of phenotypes of peripheral blood mononuclear cells

1 reference

12 December 2020

Platelet activating factor mediates interleukin-2-induced lung injury in the rat

1 reference

12 December 2020

Clinical toxicity of interleukin-2.

1 reference

12 December 2020

Immunochemotherapy with recombinant interleukin-2 and adriamycin in primary hepatocellular carcinoma

1 reference

12 December 2020

Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma

1 reference

12 December 2020

Thymopentin and interleukin-2 in combination with 5-fluorouracil and leucovorin in metastatic colorectal adenocarcinoma: preliminary results.

1 reference

12 December 2020

Unusual gastrointestinal complications of interleukin-2 therapy

1 reference

12 December 2020

Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with dacarbazine and recombinant human interleukin-2: evaluation of hematologic and immunologic parameters and correlation with clinical response

1 reference

12 December 2020

Effects of a preoperative course of interleukin-2 on surgical and immunobiological variables in patients with colorectal cancer: a phase 2 study.

1 reference

12 December 2020

Laparotomy enhances intraperitoneal tumor growth and abrogates the antitumor effects of interleukin-2 and lymphokine-activated killer cells.

1 reference

12 December 2020

Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): binding of complement and C-reactive protein by IL-2-activated lymphocytes

1 reference

12 December 2020

Effects of interleukin-2 and interleukin-2-activated cells on in vitro myelopoiesis

1 reference

12 December 2020

Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages

1 reference

12 December 2020

Interleukin-2 binding to activated human T lymphocytes triggers generation of cyclic AMP but not of inositol phosphates

1 reference

12 December 2020

Immunotherapy for metastatic renal cell cancer: effect on the primary tumor

1 reference

12 December 2020

The systemic influence of recombinant interleukin 2 on the manifestations of lepromatous leprosy

1 reference

12 December 2020

Regulation of interleukin-2 responses by phosphatidic acid

1 reference

12 December 2020

Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma

1 reference

12 December 2020

Acute colonic pseudo-obstruction associated with interleukin-2 therapy

1 reference

12 December 2020

Phase I study of combination recombinant interleukin-2 and interferon gamma in patients with advanced malignancies

1 reference

12 December 2020

Intravenous interleukin-2 just after high dose BCNU and autologous bone marrow transplantation. Report of a multicentric French pilot study

1 reference

12 December 2020

What can we learn from a meta-analysis of trials testing the modulation of 5-FU by leucovorin? Advanced Colorectal Meta-analysis Project.

1 reference

12 December 2020

Fluctuations of plasma beta 2-microglobulin, soluble interleukin 2 receptor and interferon-gamma concentrations after adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells

1 reference

12 December 2020

Adoptive immunotherapy with interleukin-2 (IL-2) results in diminished IL-2 production by stimulated peripheral blood lymphocytes

1 reference

12 December 2020

Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapy

1 reference

12 December 2020

Natural killer activity: the definition of a function rather than a cell type

1 reference

12 December 2020

Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer and Leukemia Group B.

1 reference

12 December 2020

Inhibitory effects of alloimmune T cells on the generation of cytolytic responses of lymphokine-activated killer cells

1 reference

12 December 2020

HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy

1 reference

12 December 2020

Subcutaneous interleukin-2 and interferon-alpha 2b in patients with metastatic renal cell cancer: the German outpatient experience

1 reference

12 December 2020

The involvement of human tumor necrosis factors-alpha and -beta in the mixed lymphocyte reaction

1 reference

12 December 2020

Adoptive immunotherapy with high-dose interleukin-2: kinetics of circulating progenitors correlate with interleukin-6, granulocyte colony-stimulating factor level

1 reference

12 December 2020

A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma

1 reference

12 December 2020

Peripheral blood lymphocyte response to exogenous interleukin 2 by PHA-prestimulated and non-PHA-prestimulated cells in patients with cancer

1 reference

12 December 2020

In vivo administration of interleukin-2 turns on anergic self-reactive T cells and leads to autoimmune disease

1 reference

12 December 2020

Treatment of non-Hodgkin's lymphoma

1 reference

12 December 2020

Lymphokine (IL-2 and TNF-alpha) mediated cytolytic activity against glioma cells in vitro.

1 reference

12 December 2020

Interleukin-2 activated T cells (T-LAK) express CD16 antigen and are triggered to target cell lysis by bispecific antibody

1 reference

12 December 2020

Effect of granulocyte-macrophage colony-stimulating factor on lymphokine-activated killer cell induction

1 reference

12 December 2020

Haemodynamic effects induced by intravenous administration of high doses of r-Met Hu IL-2 [ala-125] in patients with advanced cancer.

1 reference

12 December 2020

Acute pancreatitis associated with high-dose interleukin-2 immunotherapy for malignant melanoma

1 reference

12 December 2020

The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells.

1 reference

12 December 2020

Interleukin-2-induced lymphoproliferative responses

1 reference

12 December 2020

Interleukin-2 and interferon-alpha-2a outpatient therapy for metastatic renal cell carcinoma

1 reference

12 December 2020

Antierythrocyte autoantibody formation after therapy with interleukin-2 and gamma-interferon

1 reference

12 December 2020

Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy

1 reference

12 December 2020

Hypoprothrombinemia associated with interleukin-2 therapy: correction with vitamin K

1 reference

12 December 2020

Treatment with tumour infiltrating lymphocytes and interleukin-2 in patients with metastatic melanoma: a pilot study

1 reference

12 December 2020

Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus.

1 reference

12 December 2020

Tumour necrosis factor-alpha enhances the cytolytic and cytostatic capacity of interleukin-2 activated killer cells

1 reference

12 December 2020

Immunologic effects on peripheral lymphoid cells from patients with chronic hepatitis type B during administration of recombinant interleukin 2.

1 reference

12 December 2020

IL-4 increases IL-2 production by T cells in response to accessory cell-independent stimuli

1 reference

12 December 2020

In Vivo Effects of Multiple Cycles of Recombinant Interleukin-2 (IL2) on Peripheral Granulocyte-macrophage Hematopoietic Progenitors Circulating in the Blood of Cancer Patients

1 reference

12 December 2020

Metastatic renal cell cancer: interleukin-2 toxicity induced by contrast agent injection

1 reference

12 December 2020

Interleukin 2 and the treatment of leukemia and lymphoma

1 reference

12 December 2020

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

12 December 2020

Effects of recombinant interferon-gamma and interleukin-2 on the generation of lymphokine-activated killer cells in vitro

1 reference

12 December 2020

Histologic changes in superficial basal cell epithelioma and Bowen's disease by intralesional injection of recombinant interleukin 2: recombinant interleukin 2 may induce redifferentiation of malignant tumor cells in vivo

1 reference

12 December 2020

Haemodynamic effects of recombinant interleukin-2 administered by constant infusion

1 reference

12 December 2020

Intradermal recombinant interleukin 2 enhances peripheral blood T-cell responses to mitogen and antigens in patients with lepromatous leprosy

1 reference

12 December 2020

Antibiotic prophylaxis to prevent catheter-related infections in recombinant interleukin-2-treated patients

1 reference

12 December 2020

High serum and ascitic soluble interleukin-2 receptor alpha levels in advanced epithelial ovarian cancer

1 reference

12 December 2020

Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity

1 reference

12 December 2020

Differential central nervous system responses following single and multiple recombinant interleukin-2 infusions

1 reference

12 December 2020

Effects of a preoperative therapy with interleukin-2 on surgery-induced lymphocytopenia in cancer patients

1 reference

12 December 2020

Interactive effects of alpha-interferon A/D and interleukin 2 on murine lymphokine-activated killer activity: analysis at the effector and precursor level

1 reference

12 December 2020

Colonic perforation. An unusual complication of therapy with high-dose interleukin-2

1 reference

12 December 2020

Recombinant interleukin 2 for metastatic renal cell carcinoma in haemodialysis patients

1 reference

12 December 2020

Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2

1 reference

12 December 2020

Recombinant interleukin-2 activates peripheral blood lymphocytes from children with acute leukemia to kill autologous leukemic cells

1 reference

12 December 2020

Suppression of human immunoglobulin synthesis by interleukin-4 in tandem with interleukin-2 through large granular lymphocytes

1 reference

12 December 2020

Tumour regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Preliminary report

1 reference

12 December 2020

Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma

1 reference

12 December 2020

Augmentation of the lymphokine-activated killer cell response in head and neck cancer patients by combination interleukin-2 and interferon-alpha

1 reference

12 December 2020

Altered tryptophan and neopterin metabolism in cancer patients treated with recombinant interleukin 2

1 reference

12 December 2020

Activation of the Na+ /K+ -ATPase by interleukin-2

1 reference

12 December 2020

Measurement of serum interleukin-2 activity

1 reference

12 December 2020

Colonic ischemia complicating immunotherapy with interleukin-2 and interferon-alpha

1 reference

12 December 2020

The IL-2/IL-2 receptor system: a current overview

1 reference

12 December 2020

Delayed reactions to contrast media after interleukin-2 immunotherapy

1 reference

12 December 2020

Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol.

1 reference

12 December 2020

Chest roentgenographic abnormalities in IL-2 recipients. Incidence and correlation with clinical parameters.

1 reference

12 December 2020

Strategies for improving antitumor activity utilizing IL-2: preclinical models and analysis of antitumor activity of lymphocytes from patients receiving IL-2.

1 reference

12 December 2020

The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2.

1 reference

12 December 2020

Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: a National Biotherapy Study Group trial

1 reference

12 December 2020

Induction by local injections of IL-2 of antitumor effector cells and secondary production of cytokines in malignant pleural effusion

1 reference

12 December 2020

Interleukin-2 therapy with or without lymphokine-activated killer-cell infusions for low-grade non-Hodgkin's lymphomas?

1 reference

12 December 2020

Clinical trial of natural human lymphocyte-derived interleukin 2 in cancer patients: Effects on cytokine production and suppressor cell status

1 reference

12 December 2020

IL-2 induces IL-6 production in human monocytes.

1 reference

12 December 2020

A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma

1 reference

12 December 2020

Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo

1 reference

12 December 2020

Pathophysiology of the immune system in elderly subjects with or without diabetes and variations after recombinant interleukin-2.

1 reference

12 December 2020

Regional administration of lymphokine-activated killer cells can be superior to intravenous application

1 reference

12 December 2020

Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer

1 reference

12 December 2020

In vivo treatment with interferon causes augmentation of IL-2 induced lymphokine-activated killer cells in the organs of mice

1 reference

12 December 2020

Aggressive chemotherapy combined with G-CSF and maintenance therapy with interleukin-2 for patients with advanced myelodysplastic syndrome, subacute or secondary acute myeloid leukemia--initial results

1 reference

12 December 2020

Eosinophil colony-stimulating factor induced by administration of interleukin-2 into the pleural cavity of patients with malignant pleurisy

1 reference

12 December 2020

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

12 December 2020

Lymphokine-activated killer (LAK) therapy for advanced renal cell carcinoma: clinical study on arterial LAK therapy and experimental study on LAK cell activity

1 reference

12 December 2020

Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma

1 reference

12 December 2020

Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy

1 reference

12 December 2020

Pretreatment natural killer antigen density correlates to clinical response in tumor patients receiving long-term subcutaneous recombinant interleukin-2 and recombinant interferon-alpha

1 reference

12 December 2020

Can oncogene (RAS) activation predict susceptibility of human melanoma to activated lymphocytes and, therefore, the clinical response of such neoplasms to adoptive immunotherapy?

1 reference

12 December 2020

Phase I study of interleukin-2 and interferon alfa-2a as outpatient therapy for patients with advanced malignancy

1 reference

12 December 2020

Lymphokine-activated killer (LAK) cells: interferon-gamma synergizes with interleukin-2 to induce LAK cytotoxicity in homogeneous leukemic preparations

1 reference

12 December 2020

A direct comparison of immunological and clinical effects of interleukin 2 with and without interferon-alpha in humans

1 reference

12 December 2020

Reversible cardiomyopathy after high-dose interleukin-2 therapy

1 reference

12 December 2020

Recombinant interleukin-2 in metastatic renal cell carcinoma—A European multicentre phase II study

1 reference

12 December 2020

Pulmonary toxicity of recombinant interleukin-2 plus lymphokine-activated killer cell therapy

1 reference

12 December 2020

Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response

1 reference

12 December 2020

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

1 reference

12 December 2020

Effects of arachidonic acid metabolites and other compounds on the CTLL assay for interleukin-2

1 reference

12 December 2020

Cardiomyopathy after acute myocardial infarction after therapy with interleukin-2 and tumour infiltrating lymphocytes

1 reference

12 December 2020

A phase II study of recombinant interleukin-2 with or without recombinant interferon-beta in non-Hodgkin's lymphoma. A study of the Cancer and Leukemia Group B

1 reference

12 December 2020

Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma

1 reference

12 December 2020

Thyroid Function Abnormalities Associated with the Chronic Outpatient Administration of Recombinant Interleukin-2 and Recombinant Interferon-Alpha

1 reference

12 December 2020

Acute fatal leukoencephalopathy after interleukin-2 therapy.

1 reference

12 December 2020

Continuous intravenous interleukin-2 infusion and subcutaneous interferon-alpha in metastatic renal cell carcinoma

1 reference

12 December 2020

Fibrinolysis, thrombocytopenia, and coagulation abnormalities complicating high-dose interleukin-2 immunotherapy

1 reference

12 December 2020

Interleukin-2 induces activation of coagulation and fibrinolysis: resemblance to the changes seen during experimental endotoxaemia

1 reference

12 December 2020

Lymphokine-activated killer cells are rejected in vivo by activated natural killer cells

1 reference

12 December 2020

Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: a pilot study

1 reference

12 December 2020

Clinical experience with the combined use of recombinant interleukin-2 (IL2) and interferon alfa-2a (IFN alpha) in metastatic melanoma

1 reference

12 December 2020

Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma

1 reference

12 December 2020

Local adoptive immunotherapy of advanced head and neck tumors with LAK cells and interleukin-2.

1 reference

12 December 2020

Recombinant interleukin-2 continuous infusion in ovarian cancer patients with minimal residual disease at second-look

1 reference

12 December 2020

Adoptive immunotherapy of human cancer: the cytokine cascade and monocyte activation following high-dose interleukin 2 bolus treatment

1 reference

12 December 2020

Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy

1 reference

12 December 2020

Adverse reaction to contrast material in a patient treated with local interleukin-2

1 reference

12 December 2020

Clinical immunotherapy studies in the Surgery Branch of the U.S. National Cancer Institute: brief review

1 reference

12 December 2020

Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma

1 reference

12 December 2020

The development of neutralizing antibodies in a patient receiving subcutaneous recombinant and natural interleukin-2

1 reference

12 December 2020

In vitro combined effects of human interferons and interleukin-2 on natural cell-mediated cytotoxicity

1 reference

12 December 2020

Hypothyroidism after interleukin-2 therapy

1 reference

12 December 2020

Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen

1 reference

12 December 2020

Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types

1 reference

12 December 2020

Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected].

1 reference

12 December 2020

Acute cardiomyopathy as a consequence of treatment with interleukin-2 and interferon-alpha in a patient with metastatic carcinoma of the breast

1 reference

12 December 2020

Nosocomial sepsis associated with interleukin-2.

1 reference

12 December 2020

Pharmacokinetics of teceleukin (recombinant human interleukin-2) after intravenous or subcutaneous administration to patients with cancer

1 reference

12 December 2020

Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection

1 reference

12 December 2020

Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis

1 reference

12 December 2020

Hepatic arterial infusion of interleukin-2 in advanced hepatocellular carcinoma

1 reference

12 December 2020

Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity.

1 reference

12 December 2020

Interleukin-2 bolus therapy induces immediate and selective disappearance from peripheral blood of all lymphocyte subpopulations displaying natural killer activity: role of cell adhesion to endothelium

1 reference

12 December 2020

Short-duration in vitro interleukin-2-activated mononuclear cells for advanced cancer. A Hong Kong biotherapy pilot study trial

1 reference

12 December 2020

Crescentic IgA Glomerulonephritis following Interleukin-2 Therapy for Hepatocellular Carcinoma of the Liver

1 reference

12 December 2020

Eosinophilic myocarditis associated with high-dose interleukin-2 therapy

1 reference

12 December 2020

Modulation of IL-2- and IL-4-induced cytotoxicities in human T helper lymphocyte clones by tumor necrosis factor-alpha

1 reference

12 December 2020

Cytokine regulation of colony-stimulating factor production in cultured human synovial fibroblasts: I. Induction of GM-CSF and G-CSF production by interleukin-1 and tumor necrosis factor

1 reference

12 December 2020

[The description of a new cellular type, Pinocchio cells, induced during the treatment of solid tumors with interleukin-2]

1 reference

12 December 2020

Some theoretical and practical limitations of interleukin-2. Ten cases of advanced breast cancer treated with continuous infusion of IL-2.

1 reference

12 December 2020

Limiting dilution analysis of lymphokine-activated killer cell precursor frequencies in peripheral blood lymphocytes of cancer patients receiving interleukin-2 therapy

1 reference

12 December 2020

Interstitial nephritis in a patient receiving adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells

1 reference

12 December 2020

Generation of mouse natural killer (NK) cell activity: effect of interleukin-2 (IL-2) and interferon (IFN) on the in vivo development of natural killer cells from bone marrow (BM) progenitor cells

1 reference

12 December 2020

A Southwest Oncology Group Phase I study of the sequential combination of recombinant interferon-gamma and recombinant interleukin-2 in patients with cancer

1 reference

12 December 2020

Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma

1 reference

12 December 2020

Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2.

1 reference

12 December 2020

Sequence dependence of administration of human recombinant tumor necrosis factor and interleukin-2 in murine tumor therapy

1 reference

12 December 2020

Stimulation of prostaglandin E2 and thromboxane B2 production by human monocytes in response to interleukin-2

1 reference

12 December 2020

Interleukin-2 initiates metabolic responses associated with critical illness in humans

1 reference

12 December 2020

Angioneurotic oedema and urticaria during therapy with interleukin-2 (IL-2).

1 reference

12 December 2020

Neuropsychiatric symptoms during treatment with interleukin-2

1 reference

12 December 2020

Hypothyroidism and goiter during interleukin-2 therapy

1 reference

12 December 2020

Variable expression of the interleukin-2 receptor alpha chain and MYC genes in lymphocytes from renal cell carcinoma patients treated with interleukin-2

1 reference

12 December 2020

Transient focal neurologic deficits complicating interleukin-2 therapy

1 reference

12 December 2020

Rheumatic disease following immunotherapy

1 reference

12 December 2020

Serum CD25 levels during interleukin-2 therapy: dose dependence and correlations with clinical toxicity and lymphocyte surface sCD25 expression

1 reference

12 December 2020

Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells.

1 reference

12 December 2020

Systemic biodistribution of radioiodinated interleukin-2 in the rat

1 reference

12 December 2020

The role of immunotherapy in colorectal cancer

1 reference

12 December 2020

A phase II trial of concomitant human interleukin-2 and interferon-alpha-2a in patients with disseminated malignant melanoma

1 reference

12 December 2020

Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock.

1 reference

12 December 2020

In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy

1 reference

12 December 2020

Immunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy

1 reference

12 December 2020

Evaluation of the cardiovascular toxic effect of recombinant interleukin-2 in rats

1 reference

12 December 2020

Depot characteristics and biodistribution of interleukin-2 liposomes: importance of route of administration

1 reference

12 December 2020

Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study

1 reference

12 December 2020

Neuroimmunotherapy of human cancer with interleukin-2 and the neurohormone melatonin: its efficacy in preventing hypotension

1 reference

12 December 2020

Immune responses in humans while receiving adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells: acute anergy to mitogens and recall antigens

1 reference

12 December 2020

Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma

1 reference

12 December 2020

Tumor-infiltrating lymphocytes from human colon carcinomas. Functional and phenotypic characteristics after long-term culture in recombinant interleukin 2.

1 reference

12 December 2020

Enhancement of human natural killer cell function by the combined effects of tumor necrosis factor alpha or interleukin-1 and interferon-alpha or interleukin-2.

1 reference

12 December 2020

The neuroendocrine effects of interleukin-2 treatment

1 reference

12 December 2020

Analysis of changes in serum levels of TNF, IL-1 and IL-6 during administration of IL-2. Correlation with clinical response to treatment

1 reference

12 December 2020

Sustained outgrowth of autotumor-reactive T lymphocytes from human ovarian carcinomas in the presence of tumor necrosis factor alpha and interleukin 2

1 reference

12 December 2020

Passive immunization against tumor necrosis factor inhibits interleukin-2-induced microvascular alterations and reduces toxicity

1 reference

12 December 2020

Relation of supernatant IL-2 to steady state levels of IL-2 mRNA

1 reference

12 December 2020

Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: clinical results and immunological effects

1 reference

12 December 2020

Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-alpha. Results of a phase I clinical trial

1 reference

12 December 2020

Natural killer cells in children with malignant solid tumors. Effect of recombinant interferon-alpha and interleukin-2 on natural killer cell function against tumor cell lines

1 reference

12 December 2020

Recombinant interleukin-2-induced proteinuria: fact or artifact?

1 reference

12 December 2020

The role of autologous tumor cells in preventing lymphokine-activated killer cell induction in vitro

1 reference

12 December 2020

Nephrotic syndrome associated with recombinant interleukin-2

1 reference

12 December 2020

Malignant B-cells have receptors for and respond to interleukin-2.

1 reference

12 December 2020

Interleukin 2 infusion induces haemopoietic growth factors and modifies marrow regeneration after chemotherapy or autologous marrow transplantation

1 reference

12 December 2020

Distribution and therapeutic effect of intraarterially transferred tumor-infiltrating lymphocytes in hepatic malignancies. A preliminary report

1 reference

12 December 2020

Immunotherapy with interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study

1 reference

12 December 2020

Interleukin 2 (IL2) in the management of acute myeloid leukemia: clinical and biological findings

1 reference

12 December 2020

Interleukin-2 infusion after autologous bone marrow transplantation enhances hemopoietic regeneration

1 reference

12 December 2020

Autologous bone marrow transplantation followed by interleukin-2 in children with advanced leukemia: a pilot study

1 reference

12 December 2020

Involvement of thromboxane and neutrophils in multiple-system organ edema with interleukin-2

1 reference

12 December 2020

Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells

1 reference

12 December 2020

Pathogenesis of pulmonary edema during interleukin-2 therapy: correlation of chest radiographic and clinical findings in 54 patients

1 reference

12 December 2020

Transient thyrotoxicosis and persistent hypothyroidism due to acute autoimmune thyroiditis after interleukin-2 and interferon-alpha therapy for metastatic carcinoma: a case report

1 reference

12 December 2020

Recombinant interleukin (IL) 2-induced human B cell differentiation is mediated by autocrine IL6

1 reference

12 December 2020

Oral changes in interleukin-2 treated patients: a preliminary report

1 reference

12 December 2020

Augmentation of mouse natural killer cell activity by interferon and interferon inducers

1 reference

12 December 2020

Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro

1 reference

12 December 2020

Cytokines and cytotoxic agents in renal cell carcinoma: a review

1 reference

12 December 2020

Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma

1 reference

12 December 2020

Low-dose recombinant interleukin-2 and low-dose cyclophosphamide in metastatic breast cancer.

1 reference

12 December 2020

Indomethacin up-regulates the generation of lymphokine-activated killer-cell activity and antibody-dependent cellular cytotoxicity mediated by interleukin-2

1 reference

12 December 2020

In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors.

1 reference

12 December 2020

Hypothyroidism and goiter in a patient during treatment with interleukin-2

1 reference

12 December 2020

Sustained delivery of interleukin-2 from a poloxamer 407 gel matrix following intraperitoneal injection in mice

1 reference

12 December 2020

Interleukin-2-induced increase of a monoclonal B-cell lymphocytosis. A novel in vivo interleukin-2 effect?

1 reference

12 December 2020

Effects of interleukin-2 and interferon-alpha A/D treatment on lymphocytes from tumour-bearing mice

1 reference

12 December 2020

Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: a phase I/II study

1 reference

12 December 2020

A phase II clinical trial of adoptive immunotherapy for advanced renal cell carcinoma using mitogen-activated autologous leukocytes and continuous infusion interleukin-2

1 reference

12 December 2020

Immunologic effects of interleukin-2 adoptive immunotherapy in humans: acute in vitro anergy, in vivo antibody response to tetanus

1 reference

12 December 2020

Adverse reactions to intravenous contrast media in patients treated with interleukin-2.

1 reference

12 December 2020

Changes in laboratory results for cancer patients treated with interleukin-2

1 reference

12 December 2020

Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia--a phase II study

1 reference

12 December 2020

Effects of interleukin-2 on oxygen delivery and consumption in patients with advanced malignancy.

1 reference

12 December 2020

The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2 [corrected]

1 reference

12 December 2020

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

12 December 2020

Malignant clonal expansion of large granular lymphocytes with a Leu-11+, Leu-7- surface phenotype: in vitro responsiveness of malignant cells to recombinant human interleukin 2.

1 reference

12 December 2020

Cutaneous side effects associated with interleukin 2 administration for metastatic melanoma

1 reference

12 December 2020

Life-threatening bullous skin eruptions during interleukin-2 therapy

1 reference

12 December 2020

Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma. A multicentre phase II study

1 reference

12 December 2020

Severe intrahepatic cholestasis in patients treated with recombinant interleukin-2 and lymphokine-activated killer cells

1 reference

12 December 2020

Thrombocytopenia during immunotherapy with interleukin-2 by constant infusion

1 reference

12 December 2020

Bilateral carpal tunnel syndrome associated with interleukin 2 therapy

1 reference

12 December 2020

High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse

1 reference

12 December 2020

IL2 treatment for cancer: from biology to gene therapy

1 reference

12 December 2020

Interleukin-2 lymphokine-activated killer cell therapy of non-Hodgkin's lymphoma and Hodgkin's disease

1 reference

12 December 2020

Low-dose dopamine induces early recovery of recombinant interleukin-2--impaired renal function

1 reference

12 December 2020

Sequential proleukin (rIL-2) by continuous infusion with cisplatin and cyclophosphamide in patients with unresectable ovarian cancer

1 reference

12 December 2020

Combination chemoimmunotherapy for metastatic colorectal cancer using 5-fluorouracil, leucovorin and interleukin-2

1 reference

12 December 2020

The skin: an immunoreactive target organ during interleukin-2 administration?

1 reference

12 December 2020

Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer

1 reference

12 December 2020

Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2.

1 reference

12 December 2020

Bioavailability of interleukin-2 after reconstitution with albumin

1 reference

12 December 2020

A phase I trial of recombinant interleukin-2 combined with recombinant interferon-gamma in patients with cancer

1 reference

12 December 2020

Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma

1 reference

12 December 2020

Interleukin-2 and interferon in renal cell carcinoma.

1 reference

12 December 2020

Generation of cytotoxic NK cells in peripheral blood and bone marrow of patients with acute myelogenous leukemia after continuous infusion with recombinant interleukin-2.

1 reference

12 December 2020

Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity

1 reference

12 December 2020

Surgical resection following interleukin 2 therapy for metastatic renal cell carcinoma prolongs remission

1 reference

12 December 2020

A progress report of a phase I study of interferon-gamma and interleukin-2 and some comments on the mechanism of the toxicity due to interleukin-2

1 reference

12 December 2020

Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors.

1 reference

12 December 2020

A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma

1 reference

12 December 2020

Interleukin-2-induced lung permeability is mediated by leukotriene B4.

1 reference

12 December 2020

Induction of bone formation in an adenoid cystic carcinoma of the maxillary sinus by adoptive immunotherapy involving intra-arterial injection of lymphokine-activated killer cells and recombinant interleukin-2 in combination with radiotherapy

1 reference

12 December 2020

Utilization of interleukin-2 gene transfer in local immunotherapy of cancer

1 reference

12 December 2020

Neuropsychological and neurophysiological assessment of the central effects of interleukin-2 administration

1 reference

12 December 2020

Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy

1 reference

12 December 2020

Interleukin-2 induced mitogenesis of human peripheral blood T-lymphocytes: role of accessory cells.

1 reference

12 December 2020

Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial

1 reference

12 December 2020

Renal effects of continuous infusion of recombinant interleukin-2 in children

1 reference

12 December 2020

Phase I trial of murine monoclonal antibody L6 in combination with subcutaneous interleukin-2 in patients with advanced carcinoma of the breast, colorectum, and lung

1 reference

12 December 2020

Cardiorespiratory effects of immunotherapy with interleukin-2.

1 reference

12 December 2020

Interferon-gamma induced by administration of recombinant interleukin-2 to patients with cancer: kinetics, dose dependence, and correlation with physiological and therapeutic response.

1 reference

12 December 2020

Continuous intravenous infusion of high dose recombinant interleukin 2 for advanced lymphomas--a phase II study

1 reference

12 December 2020

Relapse after response to interleukin-2-based immunotherapy: patterns of progression and response to retreatment

1 reference

12 December 2020

Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells

1 reference

12 December 2020

Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study

1 reference

12 December 2020

Synergistic activation of human natural killer cell cytotoxicity by histamine and interleukin-2

1 reference

12 December 2020

Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma

1 reference

12 December 2020

Renal cell carcinoma treated with continuous-infusion interleukin-2 with ex vivo-activated killer cells

1 reference

12 December 2020

Controlled release of interleukin-2 from biodegradable microspheres

1 reference

12 December 2020

IL-2 infusion abrogates humoral immune responses in humans.

1 reference

12 December 2020

Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer

1 reference

12 December 2020

An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy

1 reference

12 December 2020

Phosphorylation of human interleukin-2 (IL-2)

1 reference

12 December 2020

Subcutaneous ril-2 in advanced melanoma and kidney carcinoma

1 reference

12 December 2020

Interleukin-2 and splenic enlargement

1 reference

12 December 2020

Interleukin-2 treatment-associated eosinophilia is mediated by interleukin-5 production

1 reference

12 December 2020

Binding characteristics of a monoclonal antibody against human IL-2 and its application for IL-2 measurement

1 reference

12 December 2020

Clinical impact of adoptive therapy with purified CD8 cells in HIV infection

1 reference

12 December 2020

Survival characteristics of metastatic renal cell carcinoma patients treated with lymphokine-activated killer cells plus interleukin-2

1 reference

12 December 2020

Neuroendocrine Effects of Subcutaneous Interleukin-2 Injection in Cancer Patients

1 reference

12 December 2020

Contrast medium "recalls" interleukin-2 toxicity

1 reference

12 December 2020

A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma

1 reference

12 December 2020

Systemic administration of recombinant methionyl human interleukin-2 (Ala 125) to cancer patients: clinical results

1 reference

12 December 2020

Symptom assessment and management of outpatients receiving biotherapy: the application of a symptom report form

1 reference

12 December 2020

Neuropsychiatric symptoms during treatment with interleukin-2 and interferon-α

1 reference

12 December 2020

Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer: effect on natural cytotoxicity

1 reference

12 December 2020

Transient proteinuria during interleukin-2 therapy.

1 reference

12 December 2020

IL-1 and IL-4 as reciprocal regulators of IL-2 induced lymphocyte cytotoxicity

1 reference

12 December 2020

Interleukin-2 by Inhalation: Local Therapy for Metastatic Renal Cell Carcinoma

1 reference

12 December 2020

Symptomatic exacerbation of Crohn disease after treatment with high-dose interleukin-2

1 reference

12 December 2020

Brachial plexopathy associated with interleukin‐2 therapy

1 reference

12 December 2020

Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma

1 reference

12 December 2020

Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes

1 reference

12 December 2020

High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings

1 reference

12 December 2020

A phase II study of sequential recombinant interleukin-2 followed by dacarbazine in metastatic melanoma

1 reference

12 December 2020

Pathologic findings associated with interleukin-2-based immunotherapy for cancer: a postmortem study of 19 patients

1 reference

12 December 2020

Myocardial toxic effects during recombinant interleukin-2 therapy

1 reference

12 December 2020

Randomized Study of Interleukin 2 (IL-2) Alone vs IL-2 Plus Lymphokine-Activated Killer Cells for Treatment of Melanoma and Renal Cell Cancer

1 reference

12 December 2020

Effects of in vivo administration of interleukin-2 (IL-2) and IL-4, alone and in combination, on ex vivo human basophil histamine release

1 reference

12 December 2020

The interleukin-2 receptors: insights into a complex signalling mechanism

1 reference

12 December 2020

The out-patient use of recombinant human interleukin-2 and interferon alfa-2b in advanced malignancies

1 reference

12 December 2020

Severe myocarditis following high-dose interleukin-2 administration

1 reference

12 December 2020

Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects.

1 reference

12 December 2020

Bacillus Calmette-Guerin and interleukin-2 for treatment of superficial bladder cancer

1 reference

12 December 2020

Induction of interleukin-2 receptor by tumor necrosis factor alpha on cultured ovarian tumor-associated lymphocytes

1 reference

12 December 2020

The fate of interleukin-2 after in vivo administration

1 reference

12 December 2020

Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin 2 in patients with unresectable hepatocellular carcinoma

1 reference

12 December 2020

Treatment of malignant melanoma and renal cell carcinoma with recombinant human interleukin-2: analysis of cytokine levels in sera and culture supernatants

1 reference

12 December 2020

Acute immunologic effects of interleukin-2 therapy in cancer patients: decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens

1 reference

12 December 2020

Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer

1 reference

12 December 2020

Thyroid dysfunction can predict response to immunotherapy with interleukin-2 and interferon-2 alpha

1 reference

12 December 2020

Recombinant interleukin-2-expanded tumor infiltrating lymphocytes from human renal cell cancer do not exhibit autologous tumor cell-specific cytotoxicity.

1 reference

12 December 2020

Intraperitoneal lymphokine-activated killer cell/interleukin-2 therapy in patients with intra-abdominal cancer: immunologic considerations

1 reference

12 December 2020

Clinical and immunopathological results of a phase II study of perilymphatically injected recombinant interleukin-2 in locally far advanced, nonpretreated head and neck squamous cell carcinoma

1 reference

12 December 2020

Production of fibrogenic cytokines by interleukin-2-treated peripheral blood leukocytes: expression of transforming growth factor-beta and platelet-derived growth factor B chain genes

1 reference

12 December 2020

Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta

1 reference

12 December 2020

Interleukin-2-induced dermatotoxicity resembling toxic epidermal necrolysis

1 reference

12 December 2020

Neurological ischemic attack and interleukin-2 therapy

1 reference

12 December 2020

Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study

1 reference

12 December 2020

Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial

1 reference

12 December 2020

Lymphokine-activated killer (LAK) therapy for metastatic renal cell carcinoma

1 reference

12 December 2020

Intralymphatic interleukin 2 treatment in patients with acquired immunodeficiency syndrome: preliminary experience in three cases

1 reference

12 December 2020

Continuous intra-arterial administration of recombinant interleukin-2 in low-stage bladder cancer. A phase IB study

1 reference

12 December 2020

Cutaneous response to recombinant interleukin 2 in human immunodeficiency virus 1-seropositive individuals

1 reference

12 December 2020

A phase I study including pharmacokinetics of polyethylene glycol conjugated interleukin-2.

1 reference

12 December 2020

The effect of interleukin-2 on the blood-brain barrier in the 9L gliosarcoma rat model.

1 reference

12 December 2020

Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A).

1 reference

12 December 2020

Phase I study of combination therapy with interleukin 2 and beta-interferon in patients with advanced malignancy.

1 reference

12 December 2020

Combination biotherapy utilizing interleukin-2 and alpha interferon in patients with advanced cancer: a National Biotherapy Study Group Trial

1 reference

12 December 2020

10.2165/00003495-199346030-00009

Identifiers

DOI

1 reference

PubMed ID

7693434

Dimensions Publication ID

1 August 2017

0 references

1 reference

PubMed ID

7693434